Literature DB >> 2970520

In vivo stimulation and restoration of the immune response by the noninflammatory fragment 163-171 of human interleukin 1 beta.

D Boraschi1, L Nencioni, L Villa, S Censini, P Bossù, P Ghiara, R Presentini, F Perin, D Frasca, G Doria.   

Abstract

The synthetic nonapeptide VQGEESNDK, corresponding to the fragment 163-171 of human IL-1 beta, showed in vivo immunomodulatory capacities qualitatively and quantitatively comparable to those of the mature human IL-1 beta protein. In fact, both IL-1 beta and the 163-171 fragment stimulated the immune response of normal mice and restored immune reactivities of immunocompromised animals. In addition, the synthetic IL-1 peptide was as efficient as the entire protein in inducing tumor rejection and radioprotection. On the other hand, the 163-171 fragment did not cause any of several inflammation-associated metabolic changes inducible by the whole IL-1 beta molecule in vivo: hypoferremia, hypoglycemia, hyperinsulinemia, increase in circulating corticosterone, SAA and fibrinogen, decrease in hepatic drug-metabolizing enzymes. Furthermore, at variance with IL-1 beta, the 163-171 peptide did not show the toxic effects causing shock and death in adrenalectomized mice. Thus, these results confirm our previous in vitro observations that functional domains are identifiable within the multipotent cytokine IL-1 beta, and demonstrate the biological relevance of this finding in a variety of in vivo systems. The identification of a selectively active fragment of a cytokine may thus represent a significant step towards a better directed and more rational immunotherapeutic approach.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2970520      PMCID: PMC2188995          DOI: 10.1084/jem.168.2.675

Source DB:  PubMed          Journal:  J Exp Med        ISSN: 0022-1007            Impact factor:   14.307


  34 in total

1.  Antitumor effect of recombinant human interleukin 1 alpha against murine syngeneic tumors.

Authors:  S Nakamura; K Nakata; S Kashimoto; H Yoshida; M Yamada
Journal:  Jpn J Cancer Res       Date:  1986-08

2.  Expression of biologically active human interleukin 1 subpeptides by transfected simian COS cells.

Authors:  L J Rosenwasser; A C Webb; B D Clark; S Irie; L Chang; C A Dinarello; L Gehrke; S M Wolff; A Rich; P E Auron
Journal:  Proc Natl Acad Sci U S A       Date:  1986-07       Impact factor: 11.205

3.  Structure-function analysis of murine interleukin 1: biologically active polypeptides are at least 127 amino acids long and are derived from the carboxyl terminus of a 270-amino acid precursor.

Authors:  T M DeChiara; D Young; R Semionow; A S Stern; C Batula-Bernardo; C Fiedler-Nagy; K L Kaffka; P L Kilian; S Yamazaki; S B Mizel
Journal:  Proc Natl Acad Sci U S A       Date:  1986-11       Impact factor: 11.205

4.  Immunoregulatory feedback between interleukin-1 and glucocorticoid hormones.

Authors:  H Besedovsky; A del Rey; E Sorkin; C A Dinarello
Journal:  Science       Date:  1986-08-08       Impact factor: 47.728

5.  Enhanced resistance of mice to bacterial infection induced by recombinant human interleukin-1a.

Authors:  Y Ozaki; T Ohashi; A Minami; S Nakamura
Journal:  Infect Immun       Date:  1987-06       Impact factor: 3.441

6.  Role of interleukin-1 in the depression of liver drug metabolism by endotoxin.

Authors:  P Ghezzi; B Saccardo; P Villa; V Rossi; M Bianchi; C A Dinarello
Journal:  Infect Immun       Date:  1986-12       Impact factor: 3.441

7.  A short synthetic peptide fragment of human interleukin 1 with immunostimulatory but not inflammatory activity.

Authors:  G Antoni; R Presentini; F Perin; A Tagliabue; P Ghiara; S Censini; G Volpini; L Villa; D Boraschi
Journal:  J Immunol       Date:  1986-11-15       Impact factor: 5.422

8.  In vivo immunostimulating activity of the 163-171 peptide of human IL-1 beta.

Authors:  L Nencioni; L Villa; A Tagliabue; G Antoni; R Presentini; F Perin; S Silvestri; D Boraschi
Journal:  J Immunol       Date:  1987-08-01       Impact factor: 5.422

9.  Interleukin 2 activated tumor inhibition in vivo depends on the systemic involvement of host immunoreactivity.

Authors:  G Forni; M Giovarelli; A Santoni; A Modesti; M Forni
Journal:  J Immunol       Date:  1987-06-01       Impact factor: 5.422

10.  Determination of the minimum polypeptide lengths of the functionally active sites of human interleukins 1 alpha and 1 beta.

Authors:  B Mosley; S K Dower; S Gillis; D Cosman
Journal:  Proc Natl Acad Sci U S A       Date:  1987-07       Impact factor: 11.205

View more
  10 in total

1.  Peptide-based analysis of the amino acid sequence important to the immunoregulatory function of Trypanosoma cruzi Tc52 virulence factor.

Authors:  Margarida Borges; Anabela Cordeiro Da Silva; Denis Sereno; Ali Ouaissi
Journal:  Immunology       Date:  2003-05       Impact factor: 7.397

2.  Comparison of abilities of recombinant interleukin-1 alpha and -beta and noninflammatory IL-1 beta fragment 163-171 to upregulate C3b receptors (CR1) on human neutrophils and to enhance their phagocytic capacity.

Authors:  J D Ogle; J G Noel; A Balasurbramaniam; R M Sramkoski; C K Ogle; J W Alexander
Journal:  Inflammation       Date:  1990-04       Impact factor: 4.092

3.  Enhanced protective antibody responses to PspA after intranasal or subcutaneous injections of PspA genetically fused to granulocyte-macrophage colony-stimulating factor or interleukin-2.

Authors:  C Wortham; L Grinberg; D C Kaslow; D E Briles; L S McDaniel; A Lees; M Flora; C M Snapper; J J Mond
Journal:  Infect Immun       Date:  1998-04       Impact factor: 3.441

4.  Human interleukin-1 induces a rapid relaxation of the rabbit isolated mesenteric artery.

Authors:  F Marceau; E Petitclerc; D DeBlois; P Pradelles; P E Poubelle
Journal:  Br J Pharmacol       Date:  1991-06       Impact factor: 8.739

5.  Interleukin 1 suppresses inflammation in rabbit colitis. Mediation by endogenous prostaglandins.

Authors:  F Cominelli; C C Nast; R Llerena; C A Dinarello; R D Zipser
Journal:  J Clin Invest       Date:  1990-02       Impact factor: 14.808

6.  Interleukin-1 (IL-1)-induced resistance to bacterial infection: role of the type I IL-1 receptor.

Authors:  M T Vogels; W M Eling; A Otten; J W van der Meer
Journal:  Antimicrob Agents Chemother       Date:  1995-08       Impact factor: 5.191

7.  Mucosal delivery of anti-inflammatory IL-1Ra by sporulating recombinant bacteria.

Authors:  Stefano Porzio; Paola Bossù; Paolo Ruggiero; Diana Boraschi; Aldo Tagliabue
Journal:  BMC Biotechnol       Date:  2004-10-30       Impact factor: 2.563

8.  Cytokines as cellular communicators.

Authors:  R Debets; H F Savelkoul
Journal:  Mediators Inflamm       Date:  1996       Impact factor: 4.711

9.  What Is IL-1 for? The Functions of Interleukin-1 Across Evolution.

Authors:  Diana Boraschi
Journal:  Front Immunol       Date:  2022-04-06       Impact factor: 8.786

Review 10.  From Antigen Delivery System to Adjuvanticy: The Board Application of Nanoparticles in Vaccinology.

Authors:  Diana Boraschi; Paola Italiani
Journal:  Vaccines (Basel)       Date:  2015-11-05
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.